Skip to main content

Table 1 Mean fractions of fatty acids in erythrocyte membranes of the non-human primates (n = 3 in each of the two groups) at baseline, during and after treatment with the omega-3 rich phospholipid preparation, ranked according to increasing carbon chain-length and double-bonds

From: The time course of erythrocyte membrane fatty acid concentrations during and after treatment of non-human primates with increasing doses of an omega-3 rich phospholipid preparation derived from krill-oil

Fatty acid Group Baseline Week after start of treatment
2 4 6 8 10 12 14 16 18 20
Myristic C14:0 Control 0.18% 0.16% 0.18% 0.19% 0.16% 0.13% 0.17% 0.17% 0.16% 0.14% 0.17%
Treated 0.23% 0.22% 0.22% 0.19% 0.21% 0.21% 0.20% 0.15% 0.21% 0.19% 0.20%
Palmitic C16:0 Control 20.7% 21.0% 21.6% 21.7% 21.3% 20.8% 20.5% 20.6% 21.4% 20.3% 20.8%
Treated 21.9% 22.5% 22.7% 22.0% 22.5% 23.4% 21.9% 22.5% 22.3% 21.8% 21.4%
Palmitoleic C16:1n7 Control 0.15% 0.14% 0.16% 0.15% 0.14% 0.14% 0.15% 0.14% 0.13% 0.13% 0.13%
Treated 0.27% 0.28% 0.28% 0.22% 0.20% 0.15% 0.15% 0.19% 0.23% 0.22% 0.22%
Palmitelaidic C16:1n7t Control 0.07% 0.07% 0.07% 0.07% 0.08% 0.06% 0.08% 0.07% 0.07% 0.06% 0.07%
Treated 0.12% 0.14% 0.14% 0.14% 0.15% 0.16% 0.17% 0.12% 0.13% 0.12% 0.12%
Stearic C18:0 Control 18.1% 18.1% 18.1% 18.3% 18.0% 17.6% 17.8% 18.1% 18.0% 17.8% 17.9%
Treated 15.9% 16.1% 16.0% 16.0% 16.4% 15.2% 15.7% 16.5% 16.2% 16.0% 16.0%
Oleic C18:1n9 Control 9.54% 9.49% 9.73% 9.72% 9.63% 9.50% 9.49% 9.59% 9.52% 9.30% 9.34%
Treated 10.4% 10.2% 9.98% 9.43% 9.45% 8.88% 9.14% 9.80% 9.73% 9.72% 9.46%
Elaidic C18:1n9t Control 0.14% 0.13% 0.14% 0.15% 0.14% 0.15% 0.16% 0.17% 0.12% 0.12% 0.12%
Treated 0.14% 0.15% 0.15% 0.15% 0.17% 0.18% 0.17% 0.16% 0.14% 0.13% 0.12%
Linoleic C18:2n6 Control 22.7% 22.1% 22.7% 22.5% 22.4% 23.3% 23.4% 23.6% 24.8% 25.4% 25.4%
Treated 22.4% 20.3% 20.8% 19.0% 18.9% 16.7% 17.1% 21.2% 23.4% 23.9% 24.1%
Linoelaidic C18:2n6t Control 0.30% 0.23% 0.25% 0.25% 0.19% 0.19% 0.18% 0.16% 0.17% 0.14% 0.17%
Treated 0.26% 0.21% 0.25% 0.16% 0.18% 0.15% 0.16% 0.15% 0.16% 0.14% 0.15%
alpha-linolenic C18:3n3 Control 0.20% 0.20% 0.26% 0.25% 0.27% 0.31% 0.31% 0.33% 0.38% 0.38% 0.38%
Treated 0.21% 0.22% 0.25% 0.22% 0.20% 0.18% 0.20% 0.28% 0.34% 0.35% 0.33%
gamma-linolenic C18:3n6 Control 0.10% 0.09% 0.09% 0.07% 0.10% 0.11% 0.10% 0.11% 0.10% 0.08% 0.09%
Treated 0.09% 0.09% 0.09% 0.07% 0.07% 0.04% 0.05% 0.06% 0.08% 0.07% 0.09%
Arachidic C20:0 Control 0.35% 0.35% 0.35% 0.35% 0.37% 0.35% 0.36% 0.37% 0.35% 0.37% 0.38%
Treated 0.32% 0.31% 0.33% 0.32% 0.34% 0.32% 0.32% 0.33% 0.34% 0.34% 0.37%
Eicosenoic C20:1n9 Control 0.52% 0.49% 0.51% 0.49% 0.50% 0.47% 0.45% 0.45% 0.44% 0.43% 0.45%
Treated 0.59% 0.55% 0.55% 0.51% 0.52% 0.44% 0.44% 0.46% 0.46% 0.45% 0.49%
Eicosadienoic C20:2n6 Control 0.79% 0.73% 0.70% 0.69% 0.68% 0.73% 0.73% 0.72% 0.75% 0.74% 0.74%
Treated 0.74% 0.72% 0.71% 0.64% 0.62% 0.55% 0.52% 0.69% 0.70% 0.72% 0.74%
Dihomo-g-linolenic C20:3n6 Control 1.27% 1.22% 1.23% 1.21% 1.13% 1.22% 1.23% 1.23% 1.20% 1.10% 1.12%
Treated 1.84% 1.61% 1.53% 1.15% 1.06% 0.81% 0.75% 1.12% 1.28% 1.36% 1.46%
Arachidonic C20:4n6 Control 13.9% 14.3% 13.4% 13.4% 13.7% 13.8% 13.9% 13.6% 12.8% 13.0% 12.6%
Treated 11.7% 11.9% 10.8% 10.5% 9.41% 8.49% 8.10% 8.63% 8.63% 9.53% 9.88%
Behenic C22:0 Control 0.40% 0.43% 0.36% 0.35% 0.45% 0.43% 0.41% 0.43% 0.36% 0.46% 0.40%
Treated 0.40% 0.38% 0.36% 0.42% 0.41% 0.37% 0.41% 0.38% 0.37% 0.39% 0.41%
Docosatetraenoic C22:4n6 Control 1.33% 1.33% 1.32% 1.31% 1.33% 1.34% 1.40% 1.36% 1.29% 1.30% 1.29%
Treated 1.39% 1.24% 1.11% 0.87% 0.70% 0.49% 0.39% 0.42% 0.47% 0.64% 0.74%
Docosapentaenoic C22:5n3 Control 2.10% 2.07% 2.09% 2.13% 2.13% 2.14% 2.12% 2.04% 1.95% 2.02% 2.06%
Treated 2.75% 3.18% 3.42% 3.93% 4.07% 4.36% 4.53% 4.16% 3.74% 3.65% 3.63%
Docosapentaenoic C22:5n6 Control 0.40% 0.54% 0.34% 0.36% 0.49% 0.48% 0.39% 0.41% 0.27% 0.42% 0.40%
Treated 0.41% 0.38% 0.30% 0.48% 0.43% 0.38% 0.39% 0.31% 0.29% 0.41% 0.46%
Lignoceric C24:0 Control 0.40% 0.46% 0.33% 0.30% 0.48% 0.47% 0.41% 0.39% 0.31% 0.46% 0.39%
Treated 0.39% 0.35% 0.32% 0.48% 0.44% 0.39% 0.44% 0.35% 0.32% 0.41% 0.44%
Nervonic C24:1n9 Control 0.41% 0.50% 0.30% 0.26% 0.48% 0.45% 0.39% 0.38% 0.25% 0.45% 0.33%
Treated 0.46% 0.44% 0.33% 0.58% 0.48% 0.40% 0.46% 0.33% 0.30% 0.42% 0.45%
Dose (mg phospholipids/kg bw/day) 50 150 450 0
Dose (mg [EPA/DHA]/kg bw/day) 9.35/5.48 28.0/16.4 84.1/49.3 0/0
  1. Doses of administered phospholipids and of EPA and DHA are shown at the end of the table
Back to article page

Lipids in Health and Disease

ISSN: 1476-511X